KRAS and non-small cell lung carcinoma: Mutant Kirsten rat sarcoma virus (KRAS) is expressed in most cases of PDAC and strategies involving specific inhibitors that were found to work successfully in Non-Small Cell Lung Cancer (NSCLC) therapy may be adapted suitably for PDAC.